184 related articles for article (PubMed ID: 25882803)
1. Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis.
Ali H; Orchard C; Mariveles M; Scott S; Alshafi K; Bilton D; Simmonds N
Eur Respir J; 2015 Sep; 46(3):862-5. PubMed ID: 25882803
[No Abstract] [Full Text] [Related]
2. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Güzel C; Gerçeker AA
J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
[No Abstract] [Full Text] [Related]
3. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Millar BC; Malnarcic CM; McCaughan J; Moore JE
Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
[No Abstract] [Full Text] [Related]
4. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
5. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
[No Abstract] [Full Text] [Related]
7. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
Marshall BC
Am J Respir Crit Care Med; 2004 Apr; 169(7):781-2. PubMed ID: 15044219
[No Abstract] [Full Text] [Related]
8. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
Schülin T
J Antimicrob Chemother; 2002 Feb; 49(2):403-6. PubMed ID: 11815589
[TBL] [Abstract][Full Text] [Related]
9. The clinical use of colistin in patients with cystic fibrosis.
Beringer P
Curr Opin Pulm Med; 2001 Nov; 7(6):434-40. PubMed ID: 11706322
[TBL] [Abstract][Full Text] [Related]
10. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
Berlana D; Llop JM; Manresa F; Jódar R
Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
[TBL] [Abstract][Full Text] [Related]
11. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
12. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
13. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
[No Abstract] [Full Text] [Related]
14. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
[TBL] [Abstract][Full Text] [Related]
15. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Reduction in Susceptibility Testing for
Ponce MC; Svendsen E; Steed L; Flume PA
Am J Respir Crit Care Med; 2020 Jan; 201(1):114-116. PubMed ID: 31469583
[No Abstract] [Full Text] [Related]
19. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
Moore JE; Maeda Y; Goldsmith CE; Rendall JC; Elborn JS
J Cyst Fibros; 2010 May; 9(3):237-8. PubMed ID: 20378421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
